David Kirn Sells 1,922 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 1,922 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $10.02, for a total value of $19,258.44. Following the sale, the insider directly owned 1,057,231 shares of the company’s stock, valued at $10,593,454.62. This represents a 0.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

4D Molecular Therapeutics Price Performance

NASDAQ FDMT opened at $9.53 on Thursday. The business has a 50 day simple moving average of $9.54 and a 200 day simple moving average of $9.26. 4D Molecular Therapeutics, Inc. has a one year low of $3.68 and a one year high of $12.34. The stock has a market capitalization of $498.23 million, a P/E ratio of -3.71 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The firm had revenue of $3.05 million during the quarter, compared to the consensus estimate of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. Equities analysts expect that 4D Molecular Therapeutics, Inc. will post -3.74 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. RA Capital Management L.P. lifted its holdings in shares of 4D Molecular Therapeutics by 23.9% in the fourth quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after purchasing an additional 1,090,000 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of 4D Molecular Therapeutics by 13.2% in the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock valued at $48,868,000 after purchasing an additional 611,276 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of 4D Molecular Therapeutics by 4.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,302,905 shares of the company’s stock valued at $32,272,000 after purchasing an additional 174,489 shares in the last quarter. State Street Corp lifted its holdings in shares of 4D Molecular Therapeutics by 197.5% in the fourth quarter. State Street Corp now owns 2,688,880 shares of the company’s stock valued at $20,167,000 after purchasing an additional 1,785,106 shares in the last quarter. Finally, Armistice Capital LLC lifted its holdings in shares of 4D Molecular Therapeutics by 76.6% in the fourth quarter. Armistice Capital LLC now owns 1,936,000 shares of the company’s stock valued at $14,520,000 after purchasing an additional 840,000 shares in the last quarter. Institutional investors own 99.27% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on FDMT. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Monday, April 20th. Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Chardan Capital reiterated a “buy” rating and issued a $26.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. The Goldman Sachs Group set a $33.00 price target on 4D Molecular Therapeutics in a report on Friday, May 8th. Finally, Royal Bank Of Canada increased their price target on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, March 19th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $29.88.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.